Article info
Original article
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations
- Correspondence to Dr Claudiu V Cotta, Cleveland Clinic, 9500 Euclid Avenue/L-30, Cleveland, OH 44195 USA; cottac{at}ccf.org
Citation
Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations
Publication history
- Received November 8, 2015
- Revised December 13, 2015
- Accepted December 14, 2015
- First published January 11, 2016.
Online issue publication
July 20, 2016
Article Versions
- Previous version (11 January 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/